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Progression of fibrosis involves interstitial hypercellularity,
matrix accumulation, and atrophy of epithelial structures,
resulting in loss of normal function and ultimately organ
failure. There is common agreement that the fibroblast/
myofibroblast is the cell type most responsible for interstitial
matrix accumulation and consequent structural deformations
associated with fibrosis. During wound healing and
progressive fibrotic events, fibroblasts transform into
myofibroblasts acquiring smooth muscle features, most
notably the expression of alpha-smooth muscle actin and
synthesis of mesenchymal cell-related matrix proteins. In
renal disease, glomerular mesangial cells also acquire a
myofibroblast phenotype and synthesize the same matrix
proteins. The origin of interstitial myofibroblasts during
fibrosis is a matter of debate, where the cells are proposed to
derive from resident fibroblasts, pericytes, perivascular
adventitial, epithelial, and/or endothelial sources. Regardless
of the origin of the cells, transforming growth factor-beta1
(TGF-b1) is the principal growth factor responsible for
myofibroblast differentiation to a profibrotic phenotype and
exerts its effects via Smad signaling pathways involving
mitogen-activated protein kinase and Akt/protein kinase B.
Additionally, reactive oxygen species (ROS) have important
roles in progression of fibrosis. ROS are derived from a
variety of enzyme sources, of which the nicotinamide
adenine dinucleotide phosphate (NAD(P)H) oxidase family
has been identified as a major source of superoxide and
hydrogen peroxide generation in the cardiovasculature and
kidney during health and disease. Recent evidence indicates
that the NAD(P)H oxidase homolog Nox4 is most accountable
for ROS-induced fibroblast and mesangial cell activation,
where it has an essential role in TGF-b1 signaling of fibroblast
activation and differentiation into a profibrotic myofibroblast
phenotype and matrix production. Information on the role of
ROS in mesangial cell and fibroblast signaling is incomplete,
and further research on myofibroblast differentiation during
fibrosis is warranted.
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Progression of fibrosis is remarkably similar in most organs
involving pathogenic processes of interstitial hypercellularity,
matrix accumulation, and atrophy of epithelial structures
that lead to loss of normal function and organ failure. Three
phases of fibrogenesis have been described in the kidney1 that
predictably apply to other organ systems as well. There is an
induction phase characterized by infiltration of inflammatory
cells, principally mononuclear cells or macrophages, that
release profibrogenic cytokines and growth factors. This
initial event is followed by the activation of fibroblasts to
undergo transition to myofibroblasts, which also secrete
biological active products and matrix proteins. The third
phase is ongoing synthesis and accumulation of matrix,
despite resolution of the primary stimulus. Central to the
activation of fibroblast to a profibrotic myofibroblast is
transforming growth factor-beta1 (TGF-b1), which can be
released through paracrine and autocrine pathways. The roles
of inflammatory, tubular, and vascular cells in fibrosis are
complex and multifactorial, a topic adroitly covered in
several recent reviews.2–4 In the kidney, interstitial fibrosis is a
common pathway of progressive renal diseases leading to
end-stage renal disease regardless of the etiology.5 Also,
interstitial fibrosis is the strongest morphological predictor of
clinical outcome, and is most tightly linked to progression of
disease.6 Despite the primary glomerular origin of most renal
diseases, interstitial involvement indicates a more ominous
outcome.7 With increasing morbidity associated with fibrosis
related to obesity, diabetes, and heart disease, there is
imminent importance to understand the pathophysiology
of the myofibroblast for the design of future therapeutics.
This review will discuss biological factors that lead to
myofibroblast differentiation and the origin of these cells in
the interstitium. Attention is given to TGF-b and reactive
oxygen species (ROS) as principal mediators of fibrosis, with
special emphasis on the nicotinamide adenine dinucleotide
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phosphate (NAD(P)H) oxidases of the Nox family (particu-
larly Nox4) as requisite elements in signaling of TGF-b-
induced myofibroblast differentiation.
MYOFIBROBLASTS IN FIBROSIS
Activation and transformation of fibroblasts into myofibro-
blasts was first described by Gabbiani, showing that after
injury, during wound healing, or progressive fibrotic events,
activated cells acquired smooth muscle features, including
expression of desmin, caldesmon, and SM-myosin heavy
chains and an actin isoform (alpha-smooth muscle actin,
a-SMA).8,9 Consequently, a-SMA-positive myofibroblasts were
identified as the primary cell type responsible for interstitial
matrix accumulation in fibrotic diseases, including the
kidney.8–13 Moreover, an a-SMA phenotype is considered to
be a useful marker for myofibroblast differentiation in a
number of disease settings.8–27 Similarly, an a-SMAþ
phenotype in intrinsic mesenchymal cells from a variety of
organs can be induced by prolonged culture, exposure to
cytokines such as interleukin-1, interleukin-6, and tumor
necrosis factor-a, and growth factors including platelet-derived
growth factor (PDGF), angiotensin II, and TGF-b. These
include liver fat-storing cells (Ito cells), periportal fibroblasts,
pancreatic stellate cells, breast stromal cells, lung fibroblasts,
renal mesangial cells, and kidney fibroblasts.28–35 These cells
express little to no a-SMA in their resting state; however, upon
activation in vitro or during disease, they highly express this
protein along with extracellular mesenchymal matrix proteins
collagen I, collagen III, and cellular fibronectin. More recently,
epithelial cells have been reported to undergo transition to
matrix-producing fibroblasts and a-SMAþ fibroblasts (myo-
fibroblasts) (see the section on epithelial-to-mesenchymal
transition (EMT) below). Collectively, these cells are referred
to as ‘myofibroblasts’, despite their origin.
Control of the transition of fibroblasts to myofibroblasts is
complex and involves a variety of chemical factors, extra-
cellular matrix (ECM) proteins, and mechanical microenvir-
onment8,13 (see below). Hinz13 categorized the differentiation
of fibroblasts into myofibroblasts functionally by a two-step
process where fibroblasts are activated to form proto-
myofibroblasts with contractile stress fibers in response to
locally released cytokines or changes in the composition,
organization, and mechanical property of the ECM. Proto-
myofibroblasts further differentiate into myofibroblasts by
neoexpressing a-SMA.13 These steps are believed to be
responsible for migration and repopulation of damaged
tissues, followed by matrix synthesis and contraction of
connective tissue during remodeling. Prolonged exposure to
an insult results in inappropriate matrix expansion by
myofibroblasts, leading to fibrosis and loss of tissue function.36
ACTIVATION OF MESANGIAL CELLS AND INTERSTITIAL
FIBROBLASTS IN RENAL DISEASE
The bulk of excess ECM synthesis during the progression of
chronic renal disease can be attributed to two similar
mesenchymal cell types, the glomerular mesangial cell and
the interstitial fibroblast. Mesangial cells have been suggested
to be specialized pericytes37 juxtaposed to the capillaries
within the renal glomerulus, and fibroblasts occupy the
peritubular interstitial space. Other than their location, the
two cell types are quite similar in their response to profibrotic
stimuli during disease by way of acquiring an a-SMA-positive
myofibroblast phenotype and the subsequent synthesis of
matrix proteins, including fibronectin, laminins, and type IV
collagen. When activated, both cell types also acquire the
expression of type I and III collagens,10–12,16,21,23,38–40 and
activation of both cell types upregulates an alternatively
spliced isoform of fibronectin containing extra domain
EIIIA (equivalent to ED-A in human tissues) that has an
essential role in myofibroblast differentiation (see below).
Also, a-SMA-deficient mice show enhanced cell proliferation
and type 1 procollagen expression in the interstitium
after unilateral ureteral obstruction and in mesangioprolif-
erative glomerulonephritis, suggesting that the functions
of a-SMA in these two mesenchymal cell types are similar.41
The interpretation of these seemingly paradoxical results was
that the presence or absence of an a-SMA phenotype has
opposing functions of maintaining a cell in a contractile or a
productive state, respectively. Thus, the relative presence of
a-SMA may provide suppressing or accentuating roles in
fibrosis progression.41
THE ORIGIN(S) OF MYOFIBROBLASTS
The origin(s) of interstitial myofibroblasts in fibrosis is
currently under extensive investigation, and scientific reports
in kidney, liver, and lung indicate that the cells may be
derived from one or more sources (Figure 1). Originally,
myofibroblasts were thought to be derived from intrinsic
fibroblasts that reside within the interstitium, but this simple
concept has evolved into a much more complex and
controversial area of investigation. The origins of interstitial
myofibroblasts now include activation of resident fibroblasts
or pericytes,19,20,22–26,42 expansion of perivascular fibro-
blasts,19,20,22,43–48 infiltration of circulating bone marrow-
derived fibrocytes,49–51 EMT (see below), and/or endothe-
lial–mesenchymal transition.52,53 Each mode of interstitial
encroachment results by myofibroblast migration, prolifera-
tion, and ultimately matrix expansion within the interstitial
space. EMT has become the preeminent hypothesis of renal
fibroblasts and myofibroblast encroachment into the peri-
tubular interstitium during kidney fibrosis (reviewed in
Strutz and Neilson,54 Iwano and Neilson,55 Zeisberg and
Kalluri,56 Kalluri and Neilson,57 and Liu58). EMT is based on
the reversal of an essential developmental process, known as
mesenchymal-to-epithelial transition, whereby embryonic
mesenchymal cells differentiate into the tubular epithelium.59
During the process of EMT, mechanisms are believed to exist
to reverse the mesenchymal-to-epithelial transition and
epithelial cells lose specialized differentiation markers, such
as E-cadherin and cytokeratins, and acquire mesenchymal
proteins, including a-SMA, vimentin, and fibroblast-specific
protein-1 (FSP-1) that has been associated with cell
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migration and invasiveness. According to this hypothesis, the
transformed epithelial cells synthesize matrix proteinases that
digest basement membrane proteins, thereby allowing their
migration into the interstitial space, where they proliferate
and synthesize ECM proteins commonly associated with
mesenchymal cells.54–58 Such local conversion of epithelium
was reported by Strutz et al.60 after the discovery of the
expression of FSP-1 by tubular epithelial cells during
tubulointerstitial nephritis. Since this original description,
expression of FSP-1 in injured proximal tubules, with or
without colocalization of mesenchymal markers, has been
taken as evidence of EMT as the major contributor to fibrosis
in numerous models of renal fibrosis, including ureteral
obstruction, renal ablation, diabetic nephropathy, nephro-
toxic serum nephritis, and polycystic kidney disease54–58 (see
listings in Zeisberg and Kalluri,56 Barnes and Glass,61 and
Zeisberg and Duffield62). A role for EMT in liver and lung
fibrosis has subsequently been described.63,64
The existence of EMT as a source of interstitial fibroblast
(myofibroblast) encroachment has recently become a matter
of debate.61,62,65 A large number of studies postdating the
inception of the EMT hypothesis reported that myofibro-
blasts and their secreted matrix proteins are located
exclusively in the interstitial space during experimental
fibrosis, without evidence of epithelial locations.17–26,66–74
Moreover, recent studies specifically designed to determine
the origin of myofibroblasts by utilizing the state-of-the-art
protein marker, gene reporter, or epithelial tracking strategies
observe myofibroblasts exclusively within the peritubular
interstitium in the absence of evidence for EMT in a variety
of models of renal fibrosis.19,20,22–26,42,66,72–75 The above
studies are in contrast to a number of reporter studies
illustrating a tubular origin of myofibroblasts or a-SMA-
negative collagen-producing fibroblasts that migrate into the
interstitial space76 (see the following reviews for a compre-
hensive discussion: Zeisberg and Kalluri,56 Barnes and
Glass,61 and Zeisberg and Duffield62). Also, elimination of
cells expressing FSP-1 was reported to reduce fibrosis.77
Much of the controversy over the origin of interstitial cells
rests on selection and specificity of markers for cells destined
to become interstitial matrix-producing (myo)fibroblasts.
Arguments have been made that FSP-1 is a superior and
more consistent marker of tissue fibroblasts because a-SMA
does not define the ‘universe of fibroblasts’ in that not all
fibroblasts express a-SMA60,76 and a-SMA is not expressed in
all FSP-1-positive fibroblasts.54,78,79 Indeed, the presence of
FSP-1 in epithelial cells is now used to define EMT.61 On the
other hand, FSP-1, also known as S100A4 and a variety of
other names, is not only observed in fibroblasts as the name
implies, but also can be expressed by a wide variety of cell
TGF-β
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ROS
α-SMA
Myofibroblast differentiation/
activation
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TGF-β
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Figure 1 |Proposed origin(s) of interstitial myofibroblasts during fibrosis. Myofibroblasts responsible for interstitial expansion and
structural damage during progressive organ injury have been proposed to be derived from one or more sources: (1) activation of resident
fibroblasts or pericytes, (2) infiltration of circulating bone marrow-derived fibrocytes, (3) expansion of perivascular adventitial fibroblasts,
(4) endothelial–mesenchymal (EndoMT) transition, and/or (5) epithelial-to-mesenchymal transition (EMT). Transforming growth factor-beta
(TGF-b) released via paracrine or autocrine pathways induces myofibroblast differentiation expressed by the acquisition of an alpha-smooth
muscle actin (a-SMA) phenotype and consequent synthesis of mesenchymal matrix proteins collagen type I (Col I), collagen type III (Col III),
and fibronectin EIIIA (FN). Nox NAD(P)H oxidase (Nox4)-derived reactive oxygen species (ROS) have a central role in TGF-b signaling of
myofibroblast differentiation.
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types,61,80–82 including resident fibroblasts, endothelial cells,
monocytes, or macrophages residing in or near the renal
interstitial space during fibrosis.19,20,25,26,66,83 Conversely,
others show no cross-reactivity of FSP-1 with macrophages
in renal interstitial fibrosis.76,84,85 An ongoing debate exists
over the selection of antibodies and materials used to detect
S100A4, macrophages, and other cell types, and whether
‘preferred’ reagents are being used.25,66,84 S100A4 is also
associated with cellular behaviors other than migration or
invasiveness, including cell stress, proliferation, and apopto-
sis,80,81,86 which are present during tubular injury.42,69,87
Thus, expression of FSP-1 may also be viewed as a marker for
cell activation and reflects a generalized response to cell
injury as well as cell migration and invasiveness. Varying
viewpoints exist for and against the use of either a-SMA or
S100A4 as a suitable marker of interstitial matrix-producing
cells. Answers to this debate will require additional
experimentation or the discovery of specific markers to
determine the contributions of the various aforementioned
cell types in renal interstitial fibrosis.
We are of the opinion that interstitial myofibroblasts are
derived from local fibroblasts, pericytes, or perivascular
cells.19,20,22,72,73 A cellular location of myofibroblasts in the
perivascular space also supports the histological descriptions
that mesenchymal cell-derived collagen type I or III, and/or
fibronectin are first expressed in the perivascular spaces of
arteries or arterioles in fibrosis related to cardiovascular,88
liver,89 lung,90 and kidney19,22,43–48 disease. A perivascular
source of myofibroblast encroachment becomes noteworthy
because the adventitium is a major site of ROS in the aorta
during vascular disease. The adventitia layer is less structured
in smaller arteries and arterioles, but, like the aortic
adventitia, it may be the source of perivascular myofibro-
blasts during renal disease.
MYOFIBROBLAST DIFFERENTIATION: ROLES OF TGF-b AND
ALTERNATIVELY SPLICED FIBRONECTIN EIIIA
A number of growth factors are associated with myofibroblast
differentiation, including PDGF, angiotensin II, CTGF, and
TGF-b1.13 TGF-b1 is frequently associated with a myofibroblast
a-SMA phenotype in liver, lung, and kidney disease,8,91–93 and
has been determined to be the preeminent growth factor
responsible for fibroblast activation and matrix synthesis in vitro
and during vascular disease and fibrosis.93–95 Also, TGF-b1 has a
pivotal role in fibrogenesis, in which a number of growth
factors, including PDGF and angiotensin II, exert their effects by
directly stimulating TGF-b1 production.92–98 Additionally, TGF-
b1 directly promotes myofibroblast development by inducing
expression of a-SMA phenotype.34,35,95,99,100 Similarly, TGF-b1
is considered to be the foremost growth factor for induction of
EMT in culture and in vivo.101
TGF-b1 contributes to fibrosis by the direct activation of
myofibroblast synthesis of fibronectin and laminin collagen
types I, III, IV, and VI. Of these matrix proteins, collagen type
VI and fibronectin (EIIIA) are closely associated with
myofibroblast differentiation in vitro and in disease.13
Fibronectin EIIIA is abundantly expressed during embry-
ogenesis21,102 and at the margins of healing wounds,103
whereas this domain is spliced out of plasma fibronectin
(hepatocyte derived) and many tissue-specific cells in adult
organs,104 suggesting that this matrix protein has important
and specialized functions in tissue remodeling.105 a-SMA
myofibroblasts and fibronectin EIIIA frequently colocalize in
fibrotic disease, as well as in glomerular and interstitial
lesions in kidney diseases.21,22,38,39,106,107
TGF-b1 differentially regulates the expression of fibro-
nectin EIIIA108 and induces expression of a-SMA in a variety
of mesenchymal cells in culture, including renal fibroblasts
and mesangial cells.34,100,109 Moreover, fibronectin EIIIA is
mandatory for TGF-b1 induction of myofibroblast differ-
entiation and a-SMA expression.109,110 The close proximity
of the EIIIA splice site to the Arg–Gly–Asp–Ser (RGDS) cell-
binding domain suggests that this variant has specific
functional roles.105 Certainly, fibronectin EIIIA is closely
associated with activated cells undergoing high rates of
migration, proliferation, and differentiation,21,38,39,102,103,105
and fibronectin EIIIA is considered to be the most reliable
marker of myofibroblast-derived ECM.13
ROS IN FIBROBLAST AND VASCULAR PERICYTE ACTIVATION
Accumulating evidence also indicates that oxidative stress
resulting in generation of ROS, mainly in the form of
superoxide, and hydrogen peroxide have a significant role in
the initiation and progression of cardiovascular and renal
disease.111–113 Superoxide and its dismuted derivative hydro-
gen peroxide are formed by the univalent reduction of
oxygen, generally mediated by several enzyme systems such as
xanthine oxidase, uncoupled nitric oxide synthase, myeloper-
oxidase, mitochondrial respiratory oxidases, lipoxygenases,
and the NAD(P)H oxidases of the Nox family. Exacerbated
production of ROS may directly cause macromolecular
damage, or the ROS may function as signaling molecules
that induce cellular damage or fibrogenic responses through
stress-sensitive pathways. It is important to mention that
there is growing evidence indicating that ROS are not always
damaging, especially at low levels, and in fact may act as
physiological signaling molecules.
Examples of ROS-induced fibrogenic responses include
distinct cell functions such as hypertrophy, migration,
proliferation, apoptosis, and regulation of ECM.34,106,111,112,113
Perivascular adventitial fibroblasts in the rabbit and rat
aorta,112,114–116 pericytes from the microvasculature,117 and
renal myofibroblasts34 are a major source of superoxide. These
observations become highly relevant to fibrogenesis because
not only are fibroblasts responsible for ROS generation, but
also ROS are directly linked to transmodulation of fibroblasts
to a-SMA-expressing myofibroblasts.34,35,115,118,119 Moreover,
the perivascular space is noticeably reactive and is the location
where myofibroblasts have been shown to first appear during
the course of renal fibrosis (see above).
A role for ROS in the pathogenesis of chronic renal disease
has been observed in a number of diverse models, including
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diabetic nephropathy, proliferative glomerulonephritis, im-
munoglobulin A nephropathy, hypertensive renal disease,
and fibrosis due to transient ischemic injury, renal ablation,
and ureteral obstruction (thoroughly referenced in Sachse
and Wolf,113 and Gill and Wilcox120). Importantly, the
NAD(P)H oxidases of the Nox family have recently gained
heightened attention as principal mediators of injury
associated with vascular and renal disease.111,112,120–123
Moreover, NAD(P)H oxidase has been identified as the
enzyme system that is most responsible for superoxide
generation by adventitial fibroblasts after vascular injury
of the aorta,112,116,124 and is now recognized as a key
mediator of cell proliferation and matrix accumulation in
renal disease,106,120,125–127 a topic that will be reviewed in
depth below.
NAD(P)H OXIDASES OF THE NOX FAMILY AS MAJOR SOURCES
OF ROS IN THE CARDIOVASCULATURE AND THE KIDNEY
Early studies on NAD(P)H oxidases were performed in
neutrophils and phagocytic cells, investigating the respiratory
burst NAD(P)H oxidase system.128 The phagocyte respiratory
burst oxidase or phagocyte NAD(P)H oxidase catalyzes the
NAD(P)H-dependent reduction of molecular oxygen to
generate superoxide anion, which is dismuted to hydrogen
peroxide.128,129 The phagocyte oxidase consists of two
plasma membrane-associated proteins, gp91phox (the catalytic
subunit) and p22phox, which comprise flavocytochrome b558,
as well as cytosolic factors, p47phox p67phox p40phox, and the
small GTPase Rac. Homologs of gp91phox termed Nox (for
NAD(P)H oxidase) proteins have been found in all vascular
and renal cells111,112,120,121,130–134 (Figure 2). To date, the Nox
family comprises seven members: Nox15, of which Nox2 is
gp91phox and the dual oxidases Duox1 and -2 (refs. 122, 130,
135, 136) (Figure 2). Nox1, gp91phox/Nox2, and Nox4 are the
NAD(P)H oxidase isoforms that are predominantly expressed
in the cardiovascular and cardiorenal systems. Note that the
calcium-dependent isoform Nox5 is also found in the human
vasculature, but the fact that the enzyme is not present in
rodents has hampered the investigation of its role in
cardiovascular pathologies.121,134 Moreover, no data related
to Nox5 expression in the human kidney are yet available.
Although the mechanism by which the activity of the Nox
enzymes is regulated in cardiovascular or renal cells and how
they generate ROS is not fully understood, a number of
regulatory subunits have been identified. Importantly, the
isoforms Nox1, gp91phox/Nox2, and Nox4 (but not Nox5)
appear to require p22phox as a docking subunit.130,135,136
Activation mechanisms for Nox1 are similar to those
of gp91phox/Nox2, and involve complex formation with
regulatory cytosolic subunits upon agonist stimulation.
Although Nox1 seems to primarily interact with the p47phox
homolog NoxO1 (Nox organizer 1), the p67phox homolog
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Figure 2 | Structure and molecular organization of the cardiorenal nicotinamide adenine dinucleotide phosphate (NAD(P)H)
oxidases of the Nox family. The top right panel illustrates the topology and the enzymatic reaction catalyzed by the Nox enzymes. The
other panels represent the molecular structure of the different isoforms of Nox oxidases predominantly expressed in the cardiorenal system,
gp91phox/Nox2, Nox1, and Nox4. All cardiorenal Nox proteins form a complex with p22phox, but the cytosolic subunits differ from the Nox
oxidase isoforms. FAD, flavin adenine dinucleotide; H2O2, hydrogen peroxide; O2
K, superoxide.
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NoxA1 (Nox activator 1), and Rac upon activation, it was
reported that p47phox and p67phox can partially supplant
NoxO1 and NoxA1, respectively.121,122,130,132,134–136 (Figure 2).
The most abundant Nox isoform in the cardiorenal
system is Nox4.120,130,131,135 The isoform Nox4/Renox was
cloned from the kidney, and is highly expressed in renal
tubules, fibroblasts, glomerular mesangial cells, and podo-
cytes.34,106,137–141 Nox4 is a 578-amino-acid protein that
exhibits 39% identity to the phagocyte gp91phox/Nox2 with
special conservation in the six membrane-spanning regions
and binding sites for NAD(P)H, flavin adenine dinucleotide,
and heme, the electron transfer centers that are required to
pass electrons from NAD(P)H to oxygen to form superoxide
and hydrogen peroxide.121,130,133,135–138 Evidence to date
suggest that Nox4 heterodimerization with p22phox is
sufficient to enhance the enzyme activity and it does not
require cytosolic subunits that are essential for other Nox
isoforms.130,135,136,142,143 Moreover, it was shown that the
Nox4 dehydrogenase domain exists in a conformation that
allows the spontaneous transfer of electrons from NAD(P)H
to flavin adenine dinucleotide, a property explaining the
constitutive activity of the enzyme.144 Hence, Nox4 has been
referred to as a ‘constitutively active’ enzyme that is regulated
primarily at the level of its expression in response to various
stimuli.130,133,136 As a corollary, the overall ROS output of
Nox4 may be directly Nox4 governed by its expression level.
Interestingly, it seems that transcriptional events are involved
in the chronic control of Nox4 and protein expres-
sion,118,141,145–153 whereas Nox4 is acutely regulated through
translational mechanisms without change in its mRNA
levels.34,154–157 It was suggested that stimulation with certain
agonists causes early Nox4 protein accumulation independent
of mRNA transcription by promoting translation of existing
mRNA copies.154,156,157 These types of translational-mediated
regulation mechanisms were also described for other proteins
in the kidney and implicated in the pathogenesis of renal
disease.154,158–160 Importantly, the fact that release of ROS by
Nox4 does not appear to be triggered acutely after recruitment
of cytosolic subunits upon agonist stimulation as for gp91phox/
Nox2 and Nox1 does not mean that oxidant production by
Nox4 is not controlled by activation of receptors by their
ligands (that is, agonist stimulation). Indeed, it has been
reported that Nox4 expression is rapidly upregulated by
binding of agonists such as TGF-b,34,118 angiotensin II,154
insulin or insulin-like growth factor156,161 to their membrane
receptors. As the enzyme is constitutively active, receptor
activation by these ligands results in increased Nox4-
dependent ROS production. Finally, it should be noted that
even if Nox4 regulation may occur primarily at the expression
level, Nox4 regulatory proteins that enhance its activity,
namely Poldip2 and NoxR1, have been recently identi-
fied.162,163 A potential implication of Rac in the control of
Nox4 function was suggested in endothelial cells and
mesangial cells,139,152,164 but it remains a contentious topic.
Nox4 complexity is further illustrated by the difficulty in
identifying the type of ROS (superoxide or hydrogen
peroxide) produced by the enzyme. Although it is clear that
gp91phox/Nox2 and Nox1 release primarily superoxide, the
nature of the ROS produced by Nox4 in cells or tissues is
controversial. It was documented that Nox4 generates
mostly hydrogen peroxide in vascular smooth muscle cells
or heterologous overexpression systems,130,133,145,165,166
whereas other studies in vascular smooth cells as well as in
cardiac or renal cells and tissue were able to detect Nox4-
dependent superoxide and hydrogen peroxide produc-
tion.34,106,118,141,155,167–169 It was proposed that Nox4 differs
from other Nox enzymes because the superoxide produced by
Nox4 is rapidly converted to hydrogen peroxide, thereby
rendering superoxide release from the enzyme practically
undetectable.133,165 It is of interest to note that Nox4 has been
shown to be associated with intracellular compartments or
organelles such as endoplasmic reticulum, mitochondria, or
nucleus.121,130,133,143,147,155,170 Although effective probes de-
signed to measure intracellular superoxide exist, the parti-
cular subcellular localization of Nox4 may render more
difficult the detection of the superoxide generated by the
oxidase. In addition, a negatively charged superoxide anion
does not permeate biological membranes, whereas hydrogen
peroxide obtained after superoxide dismutation is readily
permeable.130,145
NOX-DERIVED ROS AS MEDIATORS OF CARDIOVASCULAR
AND KIDNEY DISEASE: ROLE OF NOX4 IN MYOFIBROBLAST
AND MESANGIAL CELL ACTIVATION
A growing array of evidence suggests that Nox enzymes
contribute to the pathogenesis of cardiovascular and renal
disease, including hypertension, atherosclerosis, renal, or
cardiac fibrosis, as well as diabetic nephropathy or cardio-
myopathy.106,111,120,121,130–134,136,163,171–173 This is because of
the fact that multiple stimuli and agonists implicated in
these pathologies, such as TGF-b, PDGF, angiotensin II,
hyperglycemia, thrombin, urotensin, oxidized low-density
lipoprotein, insulin-like growth factor-I, vascular endothelial
growth factor, and aldosterone, have been shown to
alter the activity or expression of the Nox proteins and
subunits, and ultimately the amount of ROS pro-
duced.34,106,114,118,120,121,130,141,147,148,151,152,154–156,174–180 For
instance, upregulation of gp91phox/Nox2, Nox1, Nox4, and
p22phox (mRNA and protein) together with increased super-
oxide or hydrogen peroxide generation has been reported in
response to angiotensin II in the vasculature and the kidney
in vitro as well as in vivo.111,112,120,121,148,150,154,165,174,181–183
Similar to angiotensin II, enzyme activity or gp91phox/Nox2,
Nox1, Nox4, and p22phox expressions are upregulated in response
to hyperglycemia in vascular and renal cells, as well as in
experimental models of diabetes.106,112,141,148,151,152,155,171,181–192
Although most of the vascular and renal Nox oxidases are
regulated by profibrotic stimuli such as TGF-b, angiotensin II,
or hyperglycemia, it is important to point out that Nox4 appears
to have a predominant role in the activation of fibroblasts into
the myofibroblast phenotype and the subsequent fibrotic
processes taking place in vitro as well as in vivo. Interestingly,
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it is established that TGF-b, the most potent profibrotic factor,
specifically increases the expression of Nox4 and ROS produc-
tion in a myriad of cell types, including smooth muscle cells,
endothelial cells, hepatocytes, and fibroblasts.34,35,118,169,193–196
Moreover, we have documented that increased Nox4 expression
accounts for TGF-b-, angiotensin II-, and high glucose-mediated
oxidative stress, and renal cell activation that is accompanied by
increased ECM protein and a-SMA expression.34,106,154,155 More
specifically, Nox4 was clearly identified as a critical mediator of
high glucose- or angiotensin II-induced mesangial cell activa-
tion,106,154,155 as well as of the effects of TGF-b on kidney
fibroblast differentiation.34 However, it should be noted that it
has not been directly demonstrated that the oxidase is implicated
in TGF-b signaling in mesangial cells. Similar observations were
made in cardiac fibroblasts, where it was shown that the
induction of Nox4-dependent ROS production by TGF-b is
required for the conversion of fibroblasts into myofibroblasts,
which in turn produce a large amount of ECM.118 Nox4 is also
closely linked to TGF-b1-induced cytoskeletal changes, including
filipodia formation and F-actin assembly in human vascular
endothelial cells,196 and with stress fibers in differentiated
vascular smooth muscle cells that constitutively express
a-SMA,167 indicating that Nox-derived ROS are essential for
the maintenance of cell shape and differentiation.
The fact that these factors are known as critical mediators
of vascular, cardiac, or renal fibrosis further supports the
concept that Nox4 is the principal source of ROS that
promote oxidant-mediated tissue injury and fibrotic pro-
cesses associated with cardiovascular diseases. A causative
relationship between Nox4-derived ROS and fibrogenic
responses to renal injury was demonstrated in vivo by
showing that treatment of type 1 diabetic rats with Nox4
antisense oligonucleotides reduced ROS production and
prevented fibronectin EIIIA accumulation in the kidney.106
Similarly, genetic silencing of Nox4 with small interfering
RNA abrogates myofibroblast differentiation and fibrogenesis
in a murine model of lung fibrosis.35 Given that TGF-b-
dependent myofibroblast or modified pericyte activation is a
critical component of the fibrogenic processes leading to
tissue injury in these diseases, it is reasonable to speculate
that the deleterious effects of TGF-b may also be mediated by
Nox4-derived ROS in vivo. However, even though it is
established that Nox4 is a target of TGF-b in cultured renal
cells, direct in vivo evidence of Nox4 recruitment as an
intermediate of the pathway linking TGF-b to glomerular
and tubulointerstitial fibrosis is not yet available.
TGF-b1 AND REDOX SIGNALING IN FIBROBLAST AND
VASCULAR PERICYTE ACTIVATION
Smad/extracellular receptor kinase transcriptional pathway
in mesangial cell and fibroblast signaling
TGF-b1 exerts its effects on the cell surface by binding TGF-b
receptor type II and subsequent phosphorylation of a type 1
receptor subunit forming a heterodimeric complex. Both
TGF-b receptor type I and TGF-b receptor type II possess
serine/threonine kinase activity that subsequently signal
through a canonical pathway involving the Smad family
of transcriptional activators.197–200 In fibroblasts, TGF-b1
regulation of a-SMA transcription and myofibroblast differ-
entiation is mediated via TGF-b receptor type I phosphor-
ylation of Smad2/3 that subsequently complexes with Smad4
and translocates to the nucleus, where the dimer binds to the
promoter region of the a-SMA gene.13 Transcriptional
control is regulated by a variety of transcription factors and
the upregulation of an inhibitory Smad7.13 Phenotypic and
functional changes associated with TGF-b1-induced fibro-
blast terminal differentiation are differentially regulated by
Smad proteins.200 In some cell types, extracellular receptor
kinase (ERK) is required for activation of the Smad
pathway.201 In mesangial cells and fibroblasts, TGF-b/Smad
signaling (Smad 2/3) is tightly controlled by MAP kinase
(Ras/MAP kinase kinase/ERK) signaling cascades.202,203 Also,
ERK and Akt/protein kinase B (PKB) act as alternative
pathways in TGF-b1 signaling of matrix proteins,203–208
making these three signaling proteins the predominant
transduction pathways by this growth factor. Additionally,
TGF-b signaling of tubular epithelial cells in EMT may
involve both Smad-dependent and Smad-independent signal
transduction pathways such as p38 mitogen-activated protein
kinase.199,209,210
Role of ROS and Nox4 in mesangial cell and fibroblast
signaling
The observations that both TGF-b1 and ROS activate
fibroblast transition to an a-SMA myofibroblast and enhance
matrix synthesis34,35 indicate that these two molecules are
interrelated and may share signaling pathways in myofibro-
blast differentiation during fibrosis. ROS are known to
activate many tyrosine and serine threonine kinases,133,211,212
indicating that products of oxidation have a central role in
cell signaling. Indeed, a number of hormones, growth factors,
and cytokines induce the production of hydrogen peroxide in
a variety of target cells.211,212 A regulatory role for ROS in
PDGF- and angiotensin II-induced signal transduction is
well documented.213,214 Also, TGF-b1-induced fibronectin
synthesis by mesangial cells occurs via calcium mobili-
zation and calmodulin/calcineurin-dependent activation of
transcription factor NFAT (nuclear factor of activated
T cell) in a ROS-dependent manner.215 Similar results were
observed for TGF-b1-induced tubule epithelial cells and renal
fibroblasts.215
NAD(P)H oxidases of the Nox family have received
heightened interest as source of ROS signaling in a number of
cell types.120,121,133,173,178,216 Receptor binding of PDGF,
angiotensin II, TGF-b, and/or tumor necrosis factor-a
rapidly activates NAD(P)H oxidase, followed by intracellular
ROS generation, and activation of protein tyrosine kinases,
serine/threonine kinases, phospholipases (for example,
phospholipases C and A2), and calcium-dependent
pathways.120,121,133,173,178,216 NAD(P)H oxidase signaling
pathways can be complex and diverse, often with conflicting
data among cell type, signaling pathway, and cell behavior
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examined.120,121,133,173,178,216 Accumulating evidence points
toward the NAD(P)H oxidase of the Nox family and
particularly Nox4 as the predominant enzyme source for
ROS generation in fibrotic disease, placing this enzyme
family in a pivotal position in cell signaling (see above).
Studies by our group indicate that angiotensin II-induced
ROS generation in mesangial cells acts principally through
Nox4 as an upstream activator of ERK1/ERK2,140 Pyk-2/Src/
PDK-1,154 Akt/PKB, and/or p70S6K (refs. 139, 154, 217, 218)
pathways that lead to cell hypertrophy and increased protein
synthesis and/or fibronectin expression (Figure 3). More
specifically, Pyk-2 appears to act as a molecular scaffold
binding to both PDK-1 and Src, thereby allowing Src to
tyrosine phosphorylate and activate PDK-1, which in turn
activate its downstream effectors, Akt/PKB and p70S6K
(ref. 154). Interestingly, Nox4 and p22phox both contribute
to angiotensin II-dependent oxidative stress and fibronectin
accumulation in mesangial cells.139,154,218 Because it is known
that p22phox interacts with Nox4 and enhances its activity (see
above), it is reasonable to think that in these cells, Nox4 and
p22phox may form a complex that accounts for angiotensin II-
induced ROS generation and the subsequent fibrotic
response. However, given that gp91phox/Nox2 and Nox1 also
interact with p22phox, their role cannot be ruled out in
conditions where these subunits are also expressed in the
cells. These in vitro studies were extrapolated in vivo to type 1
diabetic nephropathy, showing colocalization of Nox4 with
a-SMA-positive mesangial cells and that antisense oligonu-
cleotides to Nox4 reduced ERK1/2 and Akt/PKB phosphor-
ylation, and inhibited glomerular hypertrophy and
fibronectin EIIIA expression.106 Interestingly, other studies
with mesangial cells exposed to advanced oxidation protein
products place an NAD(P)H oxidase, likely to be Nox4, distal
to protein kinase C activation, resulting in ECM over-
production and upregulation of TGF-b1.219 These findings
raise the possibility that Nox enzymes may also function as
upstream modulators of TGF-b1 synthesis. As mentioned
earlier, we would like to point out that the role of Nox4 in
TGF-b1-mediated ROS generation and matrix protein
accumulation has not been directly established in mesangial
cells. However, it was documented that p22phox is required for
TGF-b1-induced ROS production220 and that Src, PDK-1, or
Akt/PKB targets of Nox4-derived ROS have a role in TGF-b1-
dependent matrix accumulation205,221 in mesangial cells.
Thus, given that TGF-b1 is a major regulator of Nox4 in most
of the cell types examined (see above), it is tempting to
speculate that as for angiotensin II, the p22phox/Nox4
complex may also mediate TGF-b1 fibrotic effects in
mesangial cells. It is appealing to consider that a Nox4-
and p22phox-containing oxidase may be a pivotal signal
transducer commonly shared by both fibrotic stimuli in
mesangial cells. This is highly relevant for the design of
therapeutic strategies to prevent the initiation or progression
of fibrotic renal diseases. Whether TGF-b1-induced mesan-
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gial cell activation shares portions of these ROS signaling
cascades in Smad-related cellular events remains to be
elucidated.
Studies with fibroblasts derived from heart, lung, and
kidney also indicate that Nox4 is central to TGF-b1-induced
ROS generation and myofibroblast differentiation to a
profibrotic phenotype. For example, TGF-b1-induced transi-
tion of cardiac or pulmonary fibroblasts to a-SMA-positive
myofibroblasts is dependent on Nox4 regulation of Smad2/
3.35,118 Nox4 small interfering RNA or dominant-negative
Smad3 significantly reduced these effects in vitro,35,195 as well
as myofibroblast expansion and fibronectin synthesis in
bleomycin-induced fibrosis in vivo.35 We also showed that
Nox4 is the predominant Nox oxidase homolog in kidney
myofibroblast differentiation and expression of fibronectin
(EIIIA).34 However, unlike cardiac and pulmonary myofi-
broblasts, our results place Nox4 downstream of Smad3 and
proximal to ERK (Figure 3). Chemical inhibitors of
NAD(P)H oxidase and Nox4 small interfering RNA specifi-
cally had no effect on Smad3 phosphorylation, but blocked
downstream ERK phosphorylation and subsequent a-SMA
expression and fibronectin EIIIA synthesis (Figure 3). These
results follow a similar course described in pulmonary
vascular smooth muscle cells, where TGF-b-induced pro-
liferation occurs through a Nox4-dependent pathway down-
stream of Smad3.195 Moreover, recent studies by Haurani
et al.114 indicate that Nox4 causes feedback inhibition of its
own expression and regulates migration in adventitial
fibroblast, although the signaling pathway of this loop
remains to be elucidated. TGF-b1 also induces PAI-1
expression in human lung fibroblasts, where nuclear mito-
gen-activated protein kinase phosphatase MKP-1 is a
molecular target of Nox4-generated ROS, leading to a
sustained activation of JNK and p38 mitogen-activated
protein kinases.169 The location of these signaling molecules
with respect to Smad has not been determined. Taken
together, the data summarized above indicate that Nox4 is
essential in TGF-b-induced myofibroblast differentiation and
profibrotic cell behaviors; however, the position of Nox4-
derived ROS in the various signaling pathways varies among
fibroblast organ types.
Concluding remarks
The role of the myofibroblast in progression of fibrosis
cannot be overstated. Despite the controversy over the origin
of the interstitial myofibroblast during fibrosis, there is
common agreement that it is responsible for much of the
accumulated matrix and ultimate organ damage. Similarly,
the mesangial cell, when activated, acquires myofibroblast
features, and is most responsible for matrix synthesis in the
glomerulus during disease. Angiotensin II and TGF-b are the
growth factors with the greatest impact on myofibroblast
differentiation and synthesis of mesenchymal matrix pro-
teins. The signaling pathways used by mesangial cells and
fibroblasts are diverse, depending on the cell type and agonist
they are exposed to; however, recent studies indicate that
NAD(P)H oxidase-generated ROS are common to cell
activation. It also seems that Nox4 may be the isoform that
is most responsible for growth factor-induced ROS genera-
tion and occupies a central role in mesangial cell and
myofibroblast differentiation, and matrix synthesis. Informa-
tion on the role of ROS in angiotensin II- and TGF-b-
induced mesangial cell and fibroblast signaling is incomplete;
however, recent evidence indicates they most likely share
similar pathways. Further research in this area will shed
important information on myofibroblast differentiation and
aid in the development of therapeutic approaches to fibrosis.
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